The advanced clinical development pipeline in NASH has faced quite significant attrition (e.g., inhibitors for ASK-1, LOX-L2 or caspases).
← all excerpts
Exosomal miRNAs as Potential Biomarkers to Monitor Phosphodiesterase 5 Inhibitor Induced Anti-Fibrotic Effects on CCl<sub>4</sub> Treated Rats.
1
—
—